Last reviewed · How we verify

Multi-Allergen Oral Immunotherapy

National Institute of Allergy and Infectious Diseases (NIAID) · Phase 3 active Small molecule

Multi-Allergen Oral Immunotherapy is a Oral immunotherapy (OIT) Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for IgE-mediated allergic disease to multiple allergens, Food and/or environmental allergies (specific allergens under investigation). Also known as: Multi-Allergen OIT.

Multi-allergen oral immunotherapy desensitizes the immune system to multiple allergens by gradually exposing patients to increasing doses of allergen extracts taken by mouth, promoting immune tolerance.

Multi-allergen oral immunotherapy desensitizes the immune system to multiple allergens by gradually exposing patients to increasing doses of allergen extracts taken by mouth, promoting immune tolerance. Used for IgE-mediated allergic disease to multiple allergens, Food and/or environmental allergies (specific allergens under investigation).

At a glance

Generic nameMulti-Allergen Oral Immunotherapy
Also known asMulti-Allergen OIT
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Drug classOral immunotherapy (OIT)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

The therapy works by administering gradually increasing doses of multiple allergen extracts orally, which shifts the immune response from IgE-mediated allergic reactions toward regulatory T cell activation and IgG-blocking antibody production. This process, called oral immunological tolerance, reduces allergic symptoms and the risk of anaphylaxis upon natural allergen exposure. The multi-allergen formulation targets several common environmental or food allergens simultaneously.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Multi-Allergen Oral Immunotherapy

What is Multi-Allergen Oral Immunotherapy?

Multi-Allergen Oral Immunotherapy is a Oral immunotherapy (OIT) drug developed by National Institute of Allergy and Infectious Diseases (NIAID), indicated for IgE-mediated allergic disease to multiple allergens, Food and/or environmental allergies (specific allergens under investigation).

How does Multi-Allergen Oral Immunotherapy work?

Multi-allergen oral immunotherapy desensitizes the immune system to multiple allergens by gradually exposing patients to increasing doses of allergen extracts taken by mouth, promoting immune tolerance.

What is Multi-Allergen Oral Immunotherapy used for?

Multi-Allergen Oral Immunotherapy is indicated for IgE-mediated allergic disease to multiple allergens, Food and/or environmental allergies (specific allergens under investigation).

Who makes Multi-Allergen Oral Immunotherapy?

Multi-Allergen Oral Immunotherapy is developed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

Is Multi-Allergen Oral Immunotherapy also known as anything else?

Multi-Allergen Oral Immunotherapy is also known as Multi-Allergen OIT.

What drug class is Multi-Allergen Oral Immunotherapy in?

Multi-Allergen Oral Immunotherapy belongs to the Oral immunotherapy (OIT) class. See all Oral immunotherapy (OIT) drugs at /class/oral-immunotherapy-oit.

What development phase is Multi-Allergen Oral Immunotherapy in?

Multi-Allergen Oral Immunotherapy is in Phase 3.

What are the side effects of Multi-Allergen Oral Immunotherapy?

Common side effects of Multi-Allergen Oral Immunotherapy include Oral pruritus, Throat irritation, Gastrointestinal symptoms (nausea, abdominal discomfort), Mild allergic reactions, Anaphylaxis (rare).

Related